Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group. FUTURE II Study Group. N Engl J Med. 2007 May 10;356(19):1915-27. doi: 10.1056/NEJMoa061741. N Engl J Med. 2007. PMID: 17494925 Free article. Clinical Trial.
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
FUTURE II Study Group. FUTURE II Study Group. J Infect Dis. 2007 Nov 15;196(10):1438-46. doi: 10.1086/522864. Epub 2007 Oct 31. J Infect Dis. 2007. PMID: 18008221 Clinical Trial.
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
Ault KA; Future II Study Group. Ault KA, et al. Lancet. 2007 Jun 2;369(9576):1861-1868. doi: 10.1016/S0140-6736(07)60852-6. Lancet. 2007. PMID: 17544766
Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
Paavonen J; Future II Study Group. Paavonen J, et al. Curr Med Res Opin. 2008 Jun;24(6):1623-34. doi: 10.1185/03007990802068151. Epub 2008 Apr 23. Curr Med Res Opin. 2008. PMID: 18435868 Clinical Trial.